Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.

Elena ÉlezMaría Auxiliadora Gómez-EspañaCristina GrávalosPilar García-AlfonsoMaría José Ortiz-MoralesFerrán LosaInmaculada Alés DíazBegoña GrañaMarta Toledano-FonsecaManuel Valladares-AyerbesEduardo PoloMercedes SalgadoEva Martínez de CastroMaría José SafontAntonieta SaludAna Ruiz-CasadoJosep TaberneroMaría Del Carmen RiescoAntonio Rodriguez-ArizaEnrique Aranda

Published in: British journal of cancer (2021)

This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes.

Keyphrases

metastatic colorectal cancer
age related macular degeneration
clinical trial
endothelial cells
study protocol
vascular endothelial growth factor
phase iii
type diabetes
randomized controlled trial
climate change